Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lineage Cell Therapeutics (LCTX) Change in Accured Expenses: 2010-2025

Historic Change in Accured Expenses for Lineage Cell Therapeutics (LCTX) over the last 15 years, with Sep 2025 value amounting to $271,000.

  • Lineage Cell Therapeutics' Change in Accured Expenses rose 150.84% to $271,000 in Q3 2025 from the same period last year, while for Sep 2025 it was -$91,000, marking a year-over-year increase of 85.25%. This contributed to the annual value of -$1.7 million for FY2024, which is 26.75% up from last year.
  • As of Q3 2025, Lineage Cell Therapeutics' Change in Accured Expenses stood at $271,000, which was up 176.55% from -$354,000 recorded in Q2 2025.
  • Lineage Cell Therapeutics' Change in Accured Expenses' 5-year high stood at $21.3 million during Q4 2021, with a 5-year trough of -$18.9 million in Q1 2022.
  • Moreover, its 3-year median value for Change in Accured Expenses was -$354,000 (2025), whereas its average is -$378,545.
  • In the last 5 years, Lineage Cell Therapeutics' Change in Accured Expenses skyrocketed by 2,159.09% in 2021 and then slumped by 1,733.66% in 2022.
  • Over the past 5 years, Lineage Cell Therapeutics' Change in Accured Expenses (Quarterly) stood at $21.3 million in 2021, then crashed by 105.30% to -$1.1 million in 2022, then surged by 202.83% to $1.2 million in 2023, then tumbled by 91.65% to $97,000 in 2024, then spiked by 150.84% to $271,000 in 2025.
  • Its Change in Accured Expenses was $271,000 in Q3 2025, compared to -$354,000 in Q2 2025 and -$105,000 in Q1 2025.